Clinical effect of eltrombopagcombined with standard immunosuppression in the treatment of aplastic anemia and its influence on GATA-3,TGF-β and sFas
Objective To investigate the clinical effect of eltrombopag combined with standard immunosuppression in the treatment of aplastic anemia(AA)and its effect on GATA binding protein(GATA)-3,transforming growth factor(TGF)-β and soluble Fas(sFas)level.Methods A total of 175 patients with AA in our hospital from January 2020 to December 2023 were selected and divided into observation group(n=88)and control group(n=87).The control group was treated with standard immunosuppressive therapy,and the observation group was treated with eltrombopag on the basis of the control group.The clinical efficacy,GATA-3,TGF-β,sFas,platelet count(PLT),white blood cell(WBC),immune function and adverse reactions were compared between the two groups.Results After treatment,the total effective rate of observation group was higher than that of control group(92.05％vs 81.61％,P＜0.05).Serum levels of GATA-3,TGF-β and sFas in both groups were significantly decreased(P＜0.05),and the observation group was lower than the control group(P＜0.05).The levels of PLT and WBC in both groups were significantly higher than before(P＜0.05),and the observation group was higher than the control group(P＜0.05).The cluster of differentiation(CD)4+and CD4+/CD8+in both groups were significantly decreased than before(P＜0.05),and the observation group was lower than the control group(P＜0.05),while CD8+was significantly increased than before(P＜0.05),and the observation group was higher than the control group(P＜0.05).During treatment,there was no significant difference in adverse reactions between the two groups(P＞0.05).Conclusion Eltrombopag combined with standard immunosuppressive therapy in AA is more effective,and can improve the serum levels of GATA-3,TGF-β and sFas.
万方数据
